Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3′s diagnostic test, and focused on Power3′s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3′s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3′s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3′s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” said Helen R. Park, MS, Chief Executive Officer of Power3, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
Saba (NASDAQ:SABA), the premier people systems provider, reports that Saba customers are using Saba People Systems to manage the performance, strategic objectives, career and individual development of more than 1.25 million employees worldwide. In the past year, Saba has seen both the addition of new Performance Management Suite customers, including Baker Hughes, Cisco, Liverpool Direct, and Media-Saturn, as well as expansion into existing Saba Learning Suite and Saba Collaboration Suite customers, demonstrating the broad appeal that these solutions have to cultivate an environment where pivotal talent can deliver exceptional results.
Saba provides a new class of people systems that combine enterprise learning, people management, and collaboration technologies. Today’s people-driven enterprises are using Saba’s solutions to mobilize and engage people around new strategies and initiatives; align and connect people to accelerate the flow of business; and cultivate, capture, and share individual and collective knowhow to effectively compete and succeed.
Safe Bulkers, Inc. (NYSE: SB) Chairman and CEO, Polys Hajioannou, was interviewed by Capital Link Shipping. The video interview focused on the development of Safe Bulkers and the drybulk market in general.
The interview is featured on www.CapitalLinkShipping.com under “Interviews.”
Safe Bulkers, Inc. is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along worldwide shipping routes for some of the world’s largest users of marine drybulk transportation services. The Company’s current fleet consists of 15 drybulk vessels, all built post-2003, and the Company has contracted to acquire seven additional drybulk newbuild vessels to be delivered at various times through 2013.
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it will be hosting Investor Day 2010 at The Yale Club of New York City on Tuesday, October 5, 2010.
Investor Day 2010 will offer the investor community an opportunity to hear from key members of Safeguard�s leadership team, and from select partner companies, about their respective growth strategies, financial performance and value creation models.
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. provides growth capital for entrepreneurial and innovative life sciences and technology companies. Safeguard targets life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine and Specialty Pharmaceuticals, and technology companies in Internet / New Media, Financial Services IT and Healthcare IT with capital requirements of up to $25 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings.
No comments:
Post a Comment